ClinicalTrials.gg
RecruitingNCT07081997PaTHway60Updated Nov 5, 2026

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

A Phase 3 interventional study of Palopegteriparatide Experimental Arm and Palopegteriparatide Control Arm in Hypoparathyroidism, Endocrine System Diseases and Parathyroid Diseases, sponsored by Ascendis Pharma Bone Diseases A/S. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ascendis Pharma Bone Diseases A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 5, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Hypoparathyroidism with a site in United States — 8 open to participants now, 12 under way, 5 of them phase 3. Hypoparathyroidism · United States.

Planned enrollment
19th of 34
36 · median 41
Started
2026
with 5 others
Phase 3
13 of 43
3 open now
Primary completion
2027-06
later than 3 of 11 live
Registered
39th of 43
by date
Lead sponsor
2 of 43
Ascendis Pharma Bone Diseases A/S

Among the 43 studies in Hypoparathyroidism with a site in United States, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 3 of the 11 other live ones, and was the 39th registered.

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

Browse Hypoparathyroidism studies →

Open to participants now

8 of the 43 studies in Hypoparathyroidism with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Hypoparathyroidism with a site in United States, or all of them as a file.
02

Study summary

This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

03

Conditions studied

  • Hypoparathyroidism
  • Endocrine System Diseases
  • Parathyroid Diseases

Keywords

  • Hypoparathyroidism
  • Parathyroid Hormone
  • TransCon PTH
  • PTH(1-34)
  • Prodrug
  • Sustained Release
  • Parathyroid Hormone Replacement Therapy
  • Palopegteriparatide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, ≥18 years of age at the time of providing
  2. Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks
  3. Receiving doses of palopegteriparatide at or above 30 µg/day

    For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:

    Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening

    For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium

  4. Confirmation of laboratory parameters (Central or Local) within 2 weeks of screening visit and prior to randomization:

25(OH) vitamin D levels of ≥ 20 ng/mL (≥49 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range

  • Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)
  • Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L)

    5. 17- 40 kg/m2 at Screening

    6. If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand

    7. ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

Exclusion criteria

Exclusion criteria

  1. Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
  2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP
  3. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 µg/day, or systemic (other than as replacement therapy)
  4. Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
  5. Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening
  6. Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening
  7. Use of denosumab or romosozumab within 2 years prior to Screening. Use of raloxifene within 4 weeks prior to Screening.
  8. Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.
  9. Increased risk for osteosarcoma
  10. Women who are pregnant, intend to become pregnant, or are lactating
  11. Diagnosed drug or alcohol dependence within 3 years prior to Screening
  12. Chronic or severe cardiac disease within 26 weeks prior to Screening
  13. Cerebrovascular accident within 5 years prior to Screening.
  14. Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout
  15. Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.
  16. Known allergy or sensitivity to PTH or any of the [metacresol, mannitol, succinic acid, NaOH/(HCl)] of the investigational product
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Palopegteriparatide Experimental Arm

    Palopegteriparatide administered once daily by subcutaneous injection and titrated to an optimal dose by a novel titration algorithm.

    Combination Product: Palopegteriparatide Experimental Arm

  • Active comparator
    Palopegteriparatide Control Arm

    Palopegteriparatide administered once daily by subcutaneous injection and titrated to an optimal dose by a previously evaluated titrated algorithm

    Combination Product: Palopegteriparatide Control Arm

Interventions

  • Palopegteriparatide is administered as separate SC injection in a prefilled, single-patient use pen. Treatment duration 78 weeks.

    Also known as: Yorvipath

  • Palopegteriparatide is administered as separate SC injection in a prefilled, single-patient use pen. Treatment duration 78 weeks.

    Also known as: Yorvipath

06

What researchers measure

Primary outcomes

  1. Efficacy - Primary endpoint

    The proportion of participants with: Albumin-adjusted serum calcium (sCa) measured within 4 weeks prior to and on the Week 26 visit within the normal range (8.3-10.6 mg/dL); and independence from active vitamin D; and independence from therapeutic doses of calcium; and no increase in prescribed investigational product within 4 weeks prior to Week 26 visit.

    Time frame: 26 weeks

07

Study locations

10 of 10 sites recruiting
  • Ascendis Pharma Investigational Site
    Greeley, Colorado 80634, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Minneota, Minnesota 55905, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Reno, Nevada 89511, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    New York, New York 10022, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    New York, New York 10032, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Greenville, North Carolina 27834, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Spokane Valley, Washington 99216, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.

Of 15 phase 3 interventional studies under Hypoparathyroidism, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 86. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 24, 2025
StartActual
May 7, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Ascendis Pharma Investigational Site · Greeley, United States
  • Ascendis Pharma Investigational Site · New York, United States
  • Ascendis Pharma Investigational Site · New Brunswick, United States
across 3 updates, Sep 30, 2026 – Nov 5, 2026
Show all 3 updates
  1. Nov 5, 2026
    1 site added
    Show site
    • Ascendis Pharma Investigational Site · New Brunswick, United States
    + 1 other change: verification date
  2. Oct 20, 2026
    1 site added
    Show site
    • Ascendis Pharma Investigational Site · New York, United States
    + 1 other change: verification date
  3. Sep 30, 2026
    1 site added
    Show site
    • Ascendis Pharma Investigational Site · Greeley, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07081997
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
May 7, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Ascendis Registry Inquiries
Contact
asnd_registryinquiries@ascendispharma.com
+4561161658
Medical Director, MD
study director · Ascendis Pharma A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palopegteriparatide

Start the discussion